The Institute for Clinical and Economic Review’s (ICER) latest evidence report found that the list price of Alnylam Pharmaceuticals’ patisiran to treat hereditary transthyretin (hATTR) amyloidosis is not aligned with standard cost-effectiveness thresholds, and recommends a steep 90-95 percent discount.
“Available data on clinical effectiveness suggests that these therapies offer important advancements for patients with hATTR amyloidosis,” ICER Chief Scientific Officer Dan Ollendorf said in a statement. “However, the announced price of patisiran, even taking into account expected discounts, far exceeds commonly cited cost-effectiveness thresholds.”
According to a press release, the report will be discussed at the Midwest Comparative Effectiveness Public Advisory Council’s Sept. 13 meeting in Chicago, Illinois.
To read the full press release on ICER’s website, click here.
